ABNOM
☆ Ann an toraidhean 2022 Stiftung Warentest às a’ Ghearmailt, cha robh sàsachd luchd-cleachdaidh le ModelDerm ach beagan nas ìsle na le co-chomhairlean telemedicine pàighte.
References
Tha fios gu bheil an leusair Q-switched Nd:YAG a’ làimhseachadh nevus Ota gu h-èifeachdach agus suidheachaidhean coltach ris. Rinn sinn sgrùdadh gus faicinn dè cho math ‘s a dh’ obraich leusair high-fluence 1064 nm Q-switched Nd:YAG air spotan Mongolia ann an àiteachan neo-àbhaisteach, gun a bhith ag adhbhrachadh gum biodh an craiceann a’ lasadh. Rinn sinn sgrùdadh air 61 euslaintich leis na spotan sin, a’ sgrùdadh 70 leòintean gu h-iomlan. Chaidh leth de na leòintean a làimhseachadh leis an leusair, agus chaidh cuid eile fhàgail gun làimhseachadh airson coimeas a dhèanamh. Rinn sinn measadh air na toraidhean a’ cleachdadh sgèile agus inneal ris an canar Mexameter® gus ìrean melanin a thomhas. Chaidh euslaintich a leantainn airson cuibheasachd de 14 mìosan anns a’ bhuidheann làimhseachaidh agus 18 mìosan sa bhuidheann amharc. Aig deireadh an sgrùdaidh, lorg sinn eadar-dhealachaidhean mòra anns na sgòran sgèile agus ìrean melanin eadar na buidhnean air an làimhseachadh agus gun làimhseachadh, leis a’ bhuidheann le làimhseachadh laser a’ nochdadh builean nas fheàrr. Bha an leusair high-fluence Q-switched Nd:YAG , gun a bhith ag adhbhrachadh solas craiceann, èifeachdach agus sàbhailte airson a bhith a’ làimhseachadh na spotan neo-àbhaisteach Mongolia seo.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Rinn sinn sgrùdadh air èifeachdas agus sàbhailteachd cleachdadh làimhseachadh laser sònraichte airson ABNOM , agus choimhead sinn air dè na feartan a dh’ fhaodadh buaidh a thoirt air dè cho math ‘s a tha e ag obair. Sheall sinn air 110 euslaintich aig an robh ABNOM agus a fhuair eadar dhà agus naoi leigheasan laser. Fhuair sinn a-mach gun robh an làimhseachadh ag obair nas fheàrr mar as fhaide a chaidh a dhèanamh, ach nach robh e cho math ann an euslaintich nas sine. Dh'obraich e nas fheàrr cuideachd ann an euslaintich le craiceann nas aotroime (seòrsa III) agus raointean le buaidh nas lugha (nas lugha na 10 cm2) . Le bhith a’ faighinn melasma còmhla ri ABNOM cha robh an làimhseachadh cho èifeachdach. Cha robh coltas gu robh dath no àireamh nan raointean air an robh buaidh a’ dèanamh diofar. Fhuair timcheall air 10% de dh’ euslaintich spotan nas dorcha às deidh làimhseachadh. Thug làimhseachadh ioma-thràth toraidhean math. Tha euslaintich nas sine le craiceann nas dorcha agus spotan nas dorcha nas dualtaiche spotan nas dorcha fhaighinn às deidh làimhseachadh. Airson euslaintich le ABNOM agus melasma, tha e nas fheàrr laser lùth nas ìsle a chleachdadh gus am melasma a dhèanamh nas miosa.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ làimhseachadh
Is ann ainneamh a bhios riochdairean geala a’ cuideachadh. Eu-coltach ri melasma, faodar ABNOM a leasachadh le làimhseachadh laser agus fhàgail gus a thoirt air falbh gun a bhith a ’dol air ais. Faodar làimhseachadh laser a dhèanamh 10 gu 20 uair airson làimhseachadh ABNOM.
#QS1064 laser